Curium acquires Lantheus for $102.5/share (~$8B); Sandoz settles price-fixing for $478.5M; Latigo eyes $247M IPO for non-opioid LTG-001; BlossomHill targets $111M IPO.
August 3, 2026 10:28 AM EDT
Curium buys Lantheus for $8B; Sandoz settles price-fixing cases
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
Curium strikes up to $8B deal for radiopharma rival Lantheus
Curium compra rival de radiofármacos Lantheus por US$ 6,7 bi
Dirigée par le Belge Renaud Dehareng, Curium Pharma rachète Lantheus pour 8 milliards de dollars
Lantheus Stock Is Gaining Monday: What's Going On? - Lantheus Holdings (NASDAQ:LNTH)
Sandoz floats nearly $500M to resolve bulk of lingering US antitrust claims
Supernus, Indivior merge to create CNS-focused company and expand BD opportunities
Health Care Up Amid Deal Intrigue — Health Care Roundup
